Definium Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

DFTX$35.39+6.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share amounts)	September 30, 2026(unaudited)	December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$241,150	$257,837
Short-term investments	805,698	153,756
Prepaid and other current assets	4,911	7,727
Total current assets	1,051,759	419,320
Goodwill	19,918	19,918
Other non-current assets	2,606	862
Total assets	$1,074,283	$440,100
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable	$9,277	$5,347
Accrued expenses	37,125	20,446
2022 USD Financing Warrants	21,328	40,905
Total current liabilities	67,730	66,698
Credit facility, long-term	36,661	40,579
Other non-current liabilities	1,858	496
Total liabilities	106,249	107,773
Commitments and contingencies (Note 10)
Shareholders' equity:
Common shares, no par value, unlimited authorized as of September 30, 2026 and December 31, 2025; 136,887,557 and 98,776,265 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively	—	—
Additional paid-in capital	1,838,580	913,914
Accumulated other comprehensive (loss) income	(829)	1,085
Accumulated deficit	(869,717)	(582,672)
Total shareholders' equity	968,034	332,327
Total liabilities and shareholders' equity	$1,074,283	$440,100

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.